BeiGene Ltd. ADR | Balance Sheet

Fiscal year is January-December. All values USD Millions.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
4
44
100
368
838
14,061
Total Accounts Receivable
-
-
-
-
29
413
Inventories
-
-
-
-
11
127
Other Current Assets
1
3
6
6
36
617
Total Current Assets
4
47
106
374
913
15,219
Net Property, Plant & Equipment
7
6
7
26
63
1,323
Intangible Assets
-
-
-
-
7
6
Other Assets
-
4
4
5
55
730
Total Assets
12
53
117
406
1,047
17,614
ST Debt & Current Portion LT Debt
-
20
15
-
9
Accounts Payable
2
3
9
12
70
Income Tax Payable
-
-
-
1
9
Other Current Liabilities
10
10
12
22
62
Total Current Liabilities
32
13
35
35
150
Long-Term Debt
16
13
6
17
155
Deferred Taxes
-
-
-
1
8
Other Liabilities
1
1
1
1
25
Total Liabilities
49
28
42
53
331
Common Equity (Total)
39
53
102
353
670
Total Shareholders' Equity
39
26
74
353
670
Total Equity
37
26
74
353
684
Liabilities & Shareholders' Equity
12
53
117
406
1,047
Accumulated Minority Interest
2
-
-
-
14
Non-Equity Reserves
-
-
-
-
32
Preferred Stock (Carrying Value)
-
78
176
-
-

About BeiGene

View Profile
Address
Zhongguancun Life Science Park
Beijing Beijing 102206
China
Employees -
Website http://www.beigene.com
Updated 07/08/2019
BeiGene Ltd. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290). The company was founded by Xiao Dong Wang and John V.